Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Non-Current Assets (2018 - 2025)

China SXT Pharmaceuticals (SXTC) has 8 years of Non-Current Assets data on record, last reported at $367017.0 in Q1 2025.

  • For Q1 2025, Non-Current Assets fell 95.87% year-over-year to $367017.0; the TTM value through Mar 2025 reached $367017.0, down 95.87%, while the annual FY2025 figure was $367017.0, 95.87% down from the prior year.
  • Non-Current Assets reached $367017.0 in Q1 2025 per SXTC's latest filing, down from $8.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $11.3 million in Q1 2021 and bottomed at $367017.0 in Q1 2025.
  • Average Non-Current Assets over 5 years is $8.3 million, with a median of $10.0 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: surged 447.67% in 2021, then tumbled 95.87% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $11.3 million in 2021, then dropped by 1.94% to $11.1 million in 2022, then decreased by 9.57% to $10.0 million in 2023, then dropped by 11.35% to $8.9 million in 2024, then crashed by 95.87% to $367017.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $367017.0 in Q1 2025, $8.9 million in Q1 2024, and $10.0 million in Q1 2023.